The prevalence of neurosensorial hearing loss among cystic fibrosis patients from Hospital de Clínicas de Porto Alegre

International Journal of Pediatric Otorhinolaryngology

Volumn 67, Issue 9, 2003, Pages 939-941

  Piltcher, Otavio Bejzman ^a   Teixeira, Vanessa Niemiec ^b   De Oliveira, Marcelo Wierzynski ^b   Scattolin, Isabella ^a   Piltcher, Simão Levin ^b  

^a Hosp de Clinicas de Porto Alegre   (Spain)

^b FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

Author keywords

Cystic fibrosis; Neurossensorial hearing loss; Ototoxicity

Indexed keywords

AMIKACIN; ANTIBIOTIC AGENT; GENTAMICIN; TOBRAMYCIN;

ACOUSTIC REFLEX; ADOLESCENT; ADULT; AGE; ARTICLE; AUDIOLOGY; CHILD; CLINICAL ARTICLE; CYSTIC FIBROSIS; HEARING TEST; HUMAN; INFECTION; OTOTOXICITY; OUTPATIENT DEPARTMENT; PERCEPTION DEAFNESS; PREVALENCE; PRIORITY JOURNAL; RHINOSINUSITIS; SPAIN;

EID: 0042622191     PISSN: 01655876     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-5876(03)00135-6     Document Type: Article

References (15)

1. Cepero R., Smith R.J., Catlin F.I., Bressler K.L., Furuta G.T., Shandera K.C. Cystic Fibrosis - an otolaryngologic perspective. Otolaryngol. Head Neck Surg. 97:1987;356-360.
2. Adams G.L., Hilger P., Warick W.J. Cystic Fibrosis. Arch. Otolaryngol. 106:1980;127-136.
3. Ramsey B.W. Drug therapy: management of pulmonary disease in patients with cystic fibrosis. NEMJ. 335:1996;179-188.
4. Rosbe K.W., Jones K.R. Usefulness of patient symptoms and nasal endoscopy in the diagnosis of chronic sinusitis. Am. J. Rhinol. 12:(3):1998;167-171.
5. Stern R.C. The diagnosis of Cystic Fibrosis. NEJM. 336:1997;487-491.
6. Wald E.R. Epidemiology, pathophysiology and etiology of sinusitis. Pediatr. Infect. Dis. J. 4:1985;51-54.
7. Sone M., Schachern P.A., Paparella M.M. Loss of spiral ganglion cells as primary manifestation of aminoglycoside ototoxicity. Hear. Res. 115:(1-2):1998;217-223. January.
8. Mulherin D., Fahy J., Grant W., Keogan M., Kavanagh B., FitzGerald M. Aminoglycoside induced ototoxicity in patients with cystic fibrosis. Ir. J. Med. Sci. 160:(6):1991;173-175. January.
9. Kahlmeter G., Dahlager J.I. Aminoglycoside toxicity - a review of clinical studies published between 1975 and 1982. J. Antimicrob. Chemother. 13:(Suppl. A):1984;9-22.
10. McRorie T.I., Bosso J., Randolph L. Aminoglycoside ototoxicity in cystic fibrosis. Evaluation by high-frequency audiometry. Am. J. Dis. Child. 143:(11):1989;1328-1332. November.
11. Katbamna B., Homnick D.N., Marks J.H. Effects of chronic tobramycin treatment on distortion product otoacoustic emissions. Ear Hear. 20:(5):1999;393-402. October.
12. Katbamna B., Homnick D.N., Marks J.H. Contralateral suppression of distortion product otoacoustic emissions in children with cystic fibrosis: effects of tobramycin. J. Am. Acad. Audiol. 9:(3):1998;172-178. January.
13. Mulherean M., Degg C. Comparison of distortion product OAE generation between a patient group requiring frequent gentamicin therapy and control subjects. Br. J. Audiol. 31:(1):1997;5-9. February.
14. Mukhopadhyay S., baer S., Blanshard J. Assesment of potential ototoxicity following high-dose nebulized tobramycin in patients with cystic fibrosis. J. Antimicrob. Chemother. 31:(3):1993;429-436. March.
15. Piltcher O., Cigana L., Friedriech J., Ribeiro F.A., da Costa S.S. Sensorineural hearing loss among sickle cell disease patients from southern Brazil. Am. J. Otolaryngol. 21:(2):2000;75-79. March-April.